CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended		165 Months Ended
	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012
Revenue			$ 200,000		$ 1,790,000
Operating expenses:
General and administrative	567,940	567,460	2,118,520	1,943,029	31,009,053
Research and development	540,789	800,341	1,926,492	3,135,200	20,595,850
Total operating expenses	1,108,729	1,367,801	4,045,012	5,078,229	51,604,903
Loss from operations	(1,108,729)	(1,367,801)	(3,845,012)	(5,078,229)	(49,814,903)
Other non-operating income (expense)
Grant income				244,479	244,479
Fair value - warrant liability	76,048	(16,177)	308,359	453,209	8,166,026
Sale of state income tax loss - net					586,442
Other noncash (expense) income, net				(115,869)	205,390
Loss on extinguishment of debt					(361,877)
Write-off of patents abandoned					(1,588,087)
Amortization of debt discount and financing costs					(11,227,870)
Interest expense - convertible notes					(2,027,930)
Interest (expense) income - net	(27,978)	(21,130)	(90,560)	(60,737)	320,496
Net loss	(1,060,659)	(1,405,108)	(3,627,213)	(4,557,147)	(55,497,834)
Preferred dividends	(419,480)	(716,780)	(1,455,940)	(2,398,794)	(10,333,754)
Loss applicable to common shares	$ (1,480,139)	$ (2,121,888)	$ (5,083,153)	$ (6,955,941)	$ (65,831,588)
Basic and diluted net loss per common share	$ (0.02)	$ (0.03)	$ (0.06)	$ (0.10)
Basic and diluted weighted-average number of common shares outstanding	88,942,763	74,904,192	83,000,064	66,731,159